{
  "$schema": "folio-library-entry/v1",
  "id": "10665-69384",
  "blocks": [
    {
      "id": "library/10665-69384/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 7,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Preparing for the introduction \nof HPV vaccines: policy and \nprogramme guidance for countries\nPreparing for the introduction of HPV vaccines:  policy and programme guidance for countries\n© World Health Organization 2006\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health\nOrganization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail:\nbookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for\nnoncommercial distribution – should be ad",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of WHO's 2006 guidance 'Preparing for the introduction of HPV vaccines: policy and programme guidance for countries', with copyright, disclaimers and a contents list. It notes that the content draws on a March 2006 technical consultation in Montreux on sexual and reproductive health programmes and HPV vaccines and lists the participating experts. The acknowledgements name the UNFPA and WHO departments involved and say the note aims to alert stakeholders in several health programmes to key issues.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/sec-000-introduction.md",
      "narrative": null,
      "content": "cer. In particular, it highlights the contributions that\nnational immunization programmes, sexual and\nreproductive health programmes, and cancer con-\ntrol programmes can make in preparing for national\nintroduction of the vaccines in the context of the\nGlobal Immunization Vision and Strategy.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the guidance highlights how immunization, sexual and reproductive health and cancer control programmes can prepare for national HPV vaccine introduction under the Global Immunization Vision and Strategy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cervical cancer and HPV infection",
      "pageStart": 7,
      "pageEnd": 9,
      "target": "../sections/sec-001-cervical-cancer-and-hpv-infection.md",
      "narrative": null,
      "content": "infection\nCancer of the cervix is the second most common\ncancer in women worldwide, with about 500 000\nnew cases and 250 000 deaths each year. Almost\n80% of cases occur in low-income countries, where\ncervical cancer is the most common cancer in\nwomen. \nVirtually all cervical cancer cases (99%) are linked\nto genital infection with human papillomavirus\n(HPV), which is the most common viral infection of\nthe reproductive tract. There are 40 different geno-\ntypes of HPV that can infect the genital area of men\nand women, including the skin of the penis, the \nvulva (the area outside the vagina), and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes cervical cancer as the second most common cancer in women worldwide, with about 500 000 cases and 250 000 deaths a year, mostly in low-income countries, and nearly all linked to HPV infection, especially types 16 and 18. It explains that HPV infection usually clears but can persist and lead to precancerous lesions over decades, which screening can detect, and that visual inspection with acetic acid and cryotherapy offer a simpler approach for low-resource settings. It also notes the 2005 World Health Assembly resolution on cancer prevention and control and early vaccine trial results showing near-complete protection.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/figure-vfig-p009",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../figures/vfig-p009.webp",
      "narrative": "draft",
      "content": "Page render with Figure 2, 'Prevalence (%) of different HPV types among women with cancer, by region': a stacked bar chart for Central/South America, North America/Europe, Northern Africa and South Asia, with segments for HPV types 16, 18, 45, 31, 33, 52, 58 and others. HPV 16 is the largest share in every region (57, 70, 68 and 53%), followed by HPV 18 (13, 15, 17 and 26%). The page also has text on HPV vaccines.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vaccines against HPV V V",
      "pageStart": 9,
      "pageEnd": 10,
      "target": "../sections/sec-002-vaccines-against-hpv-v-v.md",
      "narrative": null,
      "content": "HPV vaccines contain the major capsid L1 proteins,\nwhich self-assemble into virus-like particles (VLP) \nresembling HPV. These particles do not contain viral\ngenetic material and thus are unable to multiply,\nwhich means they are non-infectious. Two prophy-\nlactic HPV vaccines have shown excellent efﬁ cacy \nprecursor lesions related to the vaccine genotypes.\nFor the quadrivalent vaccine, protection against\ngenital warts was 95–99%. However, because of\nthe heterogeneity of HPV genotypes in different\nparts of the world (Figure 2), the impact of the\ntwo candidate vaccines may vary across regions.\nN",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that HPV vaccines are made of non-infectious virus-like particles and that two prophylactic vaccines have shown excellent efficacy against precancerous lesions linked to the vaccine types, with the quadrivalent vaccine also preventing genital warts. It notes the vaccines are expected to prevent about 70% of cervical cancers in HPV-naive women and that questions on long-term efficacy, boosters and special populations are still being studied.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Target populations for HPV immunization",
      "pageStart": 10,
      "pageEnd": 12,
      "target": "../sections/sec-003-target-populations-for-hpv-immunization.md",
      "narrative": null,
      "content": "HPV immunization \nIn deﬁ ning the target population for immunization, \na key consideration is that HPV infection is sexually\ntransmitted and is usually acquired within the ﬁ rst \nfew years following sexual debut. Ideally, therefore,\nthe vaccine should be administered before sexual\ndebut, i.e. before any risk of exposure to HPV.\nCurrent indications suggest that, initially, the \nHPV vaccines will be licensed for use in girls and\nwomen aged 9–26 years. Vaccination has been\nshown to result in high seroconversion rates in all\nage groups studied, but bridging immunogenic-\nity studies for both vaccin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Argues that HPV vaccines should be given before sexual debut and notes they will likely be licensed for girls and women aged 9–26, with stronger immune responses in young adolescents and possible catch-up vaccination. It describes the expected availability of Cervarix and Gardasil and the uncertain benefit of vaccinating males, younger children, people with HIV and pregnant women. It links vaccine introduction to WHO's reproductive health strategy and its call to use existing services as entry points.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Innovative features of HPV vaccines",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-004-innovative-features-of-hpv-vaccines.md",
      "narrative": null,
      "content": "HPV vaccines\nHPV vaccines have the potential to strengthen\ninteractions among different health services and to\nprovide a new way of preventing a common cancer\non a very large scale, as well as reducing the more\nwidespread burden of genital dysplasia and warts.\nSome of the key features of the vaccines are dis-\ncussed below.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that HPV vaccines could strengthen links between health services and prevent a common cancer as well as genital dysplasia and warts on a large scale, and introduces their key features.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "A unique opportunity",
      "pageStart": 12,
      "pageEnd": 14,
      "target": "../sections/sec-005-a-unique-opportunity.md",
      "narrative": null,
      "content": "Vaccines against HPV have several features that\nrequire special consideration. Their use requires\nnew approaches to programme delivery; the target\npopulation is different from that usually addressed\nby national immunization programmes; multiple\nstakeholders need to be involved in advocacy and\nsocial communication; and the best combination\nof vaccination and screening for cervical cancer\nprogrammes remains unclear. For the ﬁ rst time, \nsexual and reproductive health communities will be\nworking with a vaccine directed against a sexually\ntransmitted infection that is linked to a fairly com-\nmon g",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that HPV vaccines need new delivery approaches because they target adolescents rather than infants, involve many stakeholders and bring immunization programmes into the sensitive area of sexual health. It describes the Global Immunization Vision and Strategy's aim to extend immunization to other age groups and the hard priority choices cancer programmes face. It sees the vaccines as a chance to promote delayed sexual debut and condom use, which will depend on strong partnerships between programmes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "An expensive product",
      "pageStart": 14,
      "pageEnd": 14,
      "target": "../sections/sec-006-an-expensive-product.md",
      "narrative": null,
      "content": "Although the price of HPV vaccines for developing\ncountries is not yet known, it is likely to be sub-\nstantially higher than the traditional EPI vaccines, at\nleast initially, even with differential pricing between\ndeveloped- and developing-country markets.\nDiscussions are under way to obtain access to\ninternational ﬁ nancing mechanisms (e.g. through \nthe Global Alliance for Vaccines and Immuniza-\ntion – GAVI), which could potentially subsidize the \nvaccine for low-resource settings until mature,\naffordable prices are achieved. The additional cost\nof including HPV vaccines in national immunizat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that HPV vaccines are likely to cost much more than traditional EPI vaccines and that international financing, for example through GAVI, is being discussed. It warns that cost should not be the only criterion and that private-sector introduction among affluent groups could widen health inequities.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction challenges",
      "pageStart": 14,
      "pageEnd": 15,
      "target": "../sections/sec-007-introduction-challenges.md",
      "narrative": null,
      "content": "The service delivery strategy and promotion of HPV \nvaccines will need to be based on country-spe-\nciﬁ c considerations of what is affordable, feasible \nand culturally acceptable. Vaccinating young girls\nagainst cancer, and other genital diseases, caused\nby a sexually transmitted infection may be a sensi-\ntive issue in some countries and cultural settings.\nIt will be essential to avoid a harmful backlash\nagainst sexual and reproductive health and adoles-\ncent health programmes (see section on Advocacy,\ninformation and communication, page 10), and to\nensure that complementary messages about del",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses that HPV vaccine delivery must be affordable, feasible and culturally acceptable and that backlash against sexual and reproductive health programmes must be avoided. It calls for clear complementary messages on delaying sex, condom use, HIV prevention and screening, and hopes the vaccine will spur cervical screening where it is lacking.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Not business as usual",
      "pageStart": 15,
      "pageEnd": 16,
      "target": "../sections/sec-008-not-business-as-usual.md",
      "narrative": null,
      "content": "The unique features and characteristics of the HPV \nvaccines mean that all the concerned programmes\nin each country will be challenged to ﬁ nd new ways \nof working together. Moreover, as mentioned above,\npublic programmes will need to act in concert with\nthe private sector. \nAt international level, partnerships need to be\nestablished now to try to reduce the usual lag time\nbetween formal registration and availability of\nhealth-care products in developed countries and\nestablishment of a negotiated price and adequate\nproduction capacity to supply developing countries.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that HPV vaccines will require national programmes to cooperate in new ways, including with the private sector, and calls for international partnerships to shorten the delay before developing countries gain affordable access.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Advocacy, information and communication",
      "pageStart": 16,
      "pageEnd": 17,
      "target": "../sections/sec-009-advocacy-information-and-communication.md",
      "narrative": null,
      "content": "communication \nDeveloping advocacy, information and commu-\nnication programmes related to HPV vaccination,\nfor multiple stakeholders and audiences, presents\nspeciﬁ c challenges and opportunities. One chal-\nlenge is to produce a balanced and informative\npublic education and communication programme\nabout HPV, cervical cancer, and other HPV-related\ncancers and diseases, and to explain the beneﬁ ts \nand limitations of the vaccines. Managing expec-\ntations and addressing the concerns of different\nstakeholders may also be challenging. Policy guid-\nance will be needed on: how the HPV vaccines\nrelate",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses the challenges and opportunities of advocacy, information and communication on HPV vaccination, stressing balanced messages and presentation of the vaccines within a broader strategy for cervical cancer prevention and sexual and reproductive health. It lists key messages: HPV causes over 99% of cervical cancers, is very common and highly transmissible, usually causes no symptoms, and the vaccines work best before sexual debut but do not protect against all types or other STIs, so screening must continue. It advises adapting messages to local sociocultural norms, avoiding backlash linked to sexual transmission, including boys in messaging, and explaining clearly what the vaccine can and cannot do.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Action points",
      "pageStart": 17,
      "pageEnd": 19,
      "target": "../sections/sec-010-action-points.md",
      "narrative": null,
      "content": "Key actions related to advocacy, information and\ncommunication include the following:\n• Interaction between those responsible for\nadvocacy, service delivery and stewardship is\nimportant, especially to generate the evidence\nand country-speciﬁ c information (e.g. on cervi-\ncal cancer burden, HPV strains circulating in the\ncountry, age of sexual debut) needed to support\npolicy and programmes (see section on Stew-\nardship and ﬁ nancing, page 17).\n• A communication strategy on cervical cancer\ncontrol in general, and the HPV vaccines in par-\nticular, should target key stakeholders and deci-\nsion-mak",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists action points on advocacy, information and communication, such as gathering country data on cancer burden and HPV strains, tailoring communication strategies to stakeholders, decision-makers and communities, and basing health promotion on local needs. It also covers developing materials and training for health workers and addressing financing questions such as insurance coverage. It urges using HPV vaccination to strengthen existing programmes for adolescents, such as school-based education on sexual health, nutrition, tobacco and HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Service delivery",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-011-service-delivery.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Reaching target populations",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-012-reaching-target-populations.md",
      "narrative": null,
      "content": "populations\nThe vaccine licences will probably establish an age\nrange of 9–26 years for the target population. This\nage range will need to be subdivided into two cat-\negories: the primary group and the catch-up group.\nPrimary target population\nThis will most likely be girls aged 9–13 years, the\nintention being to reach them prior to sexual debut.\nEach country will need to identify the most con-\nvenient and effective way of reaching adolescents\nbefore they are likely to have begun their sexual\nlife.\nIf the new vaccine is to be introduced within an\nexisting school-based immunization programme,\ni",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the likely target populations for HPV vaccination: a primary group of girls aged 9–13, before sexual debut, and a secondary catch-up group of young women aged 14–26 who were not previously vaccinated. It weighs delivery options for the primary group, including school-based programmes, EPI or tetanus campaigns and community-based adolescent sexual and reproductive health programmes for out-of-school girls, noting limits such as school drop-out, cold-chain and staff skills. It also explains how sexual and reproductive health services can spread information to older women, stresses that screening must continue for vaccinated and older women, and warns against stand-alone vaccine delivery.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Partnerships between programmes",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-013-partnerships-between-programmes.md",
      "narrative": null,
      "content": "programmes\nProgramme approaches will need to be planned\nand organized, making the most cost-efﬁ cient \nuse of existing or, where necessary, strengthened\nservices. HPV vaccine delivery should be built on\nstructures already in place at the national level,\nfor example, the vaccine cold chain infrastruc-\nture. This will maximize cost-efﬁ ciency and avoid \nwastage and duplication, which countries can ill\nafford. While it is likely that, in many countries, the\nnational immunization programme will take the\nlead in introducing the HPV vaccine, partnerships\nwill be needed with sexual and reproductive h",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends building HPV vaccine delivery on existing structures such as the cold chain, with the immunization programme likely leading in partnership with sexual and reproductive health, adolescent health, cancer control and HIV programmes. It also calls for links with education services, civil society and the private sector.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Monitoring and evaluation",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-014-monitoring-and-evaluation.md",
      "narrative": null,
      "content": "Although the construction of an effective monitoring\nand evaluation system is a “downstream” activity,\nit is important during the preparatory stage to con-\nsider how to assess process and impact. Process \nindicators will have to be measured through routine\nnational immunization programme surveillance.\nThe impact on genital warts (with the quadrivalent\nvaccine) or on abnormalities detected on screen-\ning – such as  cervical intraepithelial neoplasia\n(CIN) I or II –  is likely to be observed sooner than\nthe impact on cervical cancer. Monitoring these\noutcomes in pilot studies may be useful for e",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Advises planning early for monitoring and evaluation, using routine immunization surveillance for process indicators and tracking earlier outcomes such as genital warts and precancerous lesions. It also calls for adverse event monitoring that captures HIV status and pregnancy, use of cancer registries or proxies, and private-sector cooperation on reporting.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Action points",
      "pageStart": 21,
      "pageEnd": 23,
      "target": "../sections/sec-015-action-points.md",
      "narrative": null,
      "content": "National programmes will need to undertake the\nfollowing actions:\n• Develop links between the many different imple-\nmenting stakeholders.\n• Deﬁ ne the primary target population, taking into \naccount the most convenient access points, and\nthe earliest age of sexual debut.\n• Address sociocultural barriers to vaccination of\nyoung adolescents.\n• Determine school attendance rates for the\n9–13-year age group.\n• Update national cervical cancer control strate-\ngies to incorporate the new HPV vaccines.\n• Plan a service delivery strategy for HPV vac-\ncines:\n– Base service delivery for the introduction o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists action points for national programmes on service delivery, such as linking stakeholders, defining the primary target group, addressing sociocultural barriers, checking school attendance and updating cervical cancer strategies. It also calls for comprehensive cervical cancer prevention including screening, treatment, vaccination and monitoring of effectiveness.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Stewardship and ﬁ nancing",
      "pageStart": 23,
      "pageEnd": 24,
      "target": "../sections/sec-016-stewardship-and-ﬁ-nancing.md",
      "narrative": null,
      "content": "health system and purchasing HPV vaccines, both\ninternationally and within national health budgets,\nmust be a high priority. Financing for the introduc-\ntion of HPV vaccine will need to be approached\nas part of an overall strategy involving a number\nof partners, both globally and within individual\ncountries, and be part of a general scaling-up of \nresources to strengthen health systems. Some of\nthe necessary ﬁ nancing decisions will be made \nat global forums, or at levels within government\nhigher than the national programme manager.\nThese decisions will be of vital importance to the\neventual i",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses that strengthening health systems and financing HPV vaccine purchase must be high priorities, with some decisions taken at global or higher government levels. It discusses the need for epidemiological data, demand forecasting and lessons from hepatitis B vaccine introduction, and the importance of international funding through GAVI, UNICEF and the PAHO Revolving Fund to expand supply and secure lower prices. It also covers government oversight of private-sector introduction, such as reporting of adverse events and post-marketing surveillance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Action points",
      "pageStart": 24,
      "pageEnd": 26,
      "target": "../sections/sec-017-action-points.md",
      "narrative": null,
      "content": "In the area of stewardship and ﬁ nancing, the fol-\nlowing actions will need to be undertaken.\n• A broad range of stakeholders should be\ninvolved in developing a strategy for a com-\nprehensive and workable introduction of HPV \nvaccines. A national HPV vaccine working group\nshould be established in each country to set\nup coordination mechanisms between health\nprogrammes, civil society and private sector.\nThis could be a subgroup of the inter-agency\ncoordinating committee of the immunization\nprogramme, with representation from sexual\nand reproductive health, cancer control, HIV, and\nyouth program",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists action points on stewardship and financing for introducing HPV vaccines, including a national HPV vaccine working group linking health programmes, civil society and the private sector, and country models to forecast demand, costs and coverage as the basis for a business case. It also calls on sexual and reproductive health programmes to help prepare funding applications to GAVI and notes that countries not eligible for GAVI support can seek technical help from WHO and UNFPA.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Epilogue",
      "pageStart": 26,
      "pageEnd": 27,
      "target": "../sections/sec-018-epilogue.md",
      "narrative": null,
      "content": "Ultimately, the decision on whether and when to\nintroduce an HPV vaccine will depend on national\npolicy in each country. An overarching consid-\neration is the importance of positioning the HPV \nvaccine within a comprehensive, integrated service\ndelivery structure. Because this vaccine “ﬁ ts” in \nseveral different programmes, effective partner-\nships will be key to any successful introduction\nprogramme. Moreover, before implementing large-\nscale HPV vaccines programmes, especially in\ndeveloping countries, several knowledge gaps will\nneed to be bridged. Also, comprehensive guidelines\nand protoco",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Concludes that each country will decide nationally on introducing HPV vaccines, which should be placed within integrated, comprehensive cervical cancer control and delivered through strong partnerships, with attention to equity so that poorer women are reached. A note added in proof reports the US FDA's June 2006 approval of the quadrivalent vaccine Gardasil for girls and women aged 9–26 and lists the cancers, warts and precancerous lesions it is intended to prevent.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-69384/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Additional resources",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-019-additional-resources.md",
      "narrative": null,
      "content": "UNFPA\nhttp://www.unfpa.org/\nWHO\nhttp://www.who.int/en/ \nhttp://www.who.int/reproductive-health\nhttp://www.who.int/cancer/en/\nhttp://www.who.int/reproductive-health/pages_resources/listing_cancer.en.html\nGIVS\nhttp://www.who.int/immunization/givs/en/index.html\nGAVI\nhttp://www.gavialliance.org/",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists web links to UNFPA, WHO, GIVS and GAVI as additional resources.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
